Characteristic | Patients, n=100 |
Sex, n (%) | |
Male Female | 62 (62) 38 (38) |
Age, years, mean (SD, range) | 62.9 (10.5, 39–83) |
Source of referral, n (%) | |
Cardiologist Lipidologist GP Stroke physician | 68 (68) 29 (29) 2 (2) 1 (1) |
Patients with CVD, n (%) | 80 (80) |
High risk* Very high risk* Patients without CVD, n (%) | 42 (42) 35 (35) 20 (20) |
FH, n (%) | 21 (21) |
Lipid profile, mmol/L, mean (SD, range) | |
Total cholesterol LDL-C TG HDL-C | 6.6 (1.9, 2.2–12.2) 4.0 (1.8, 0.7–9.8) 2.9 (1.7, 0.4–7.4) 1.4 (0.4, 0.7–2.4) |
Statin status, n (%) | |
Intolerant/some intolerance Tolerant Unknown | 56 (56) 41 (41) 3 (3) |
Lipid-lowering treatment, n (%) | |
Atorvastatin Rosuvastatin Ezetimibe Statin and ezetimibe | 33 (33) 39 (39) 28 (28) 36 (36) |
*Based on criteria from the NICE.13 14
CVD, cardiovascular disease; FH, familial hypercholesterolaemia; GP, general practitioner; HDL, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; NICE, National Institute for Health and Care Excellence; TG, triglycerides.